| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9946005 | The Annals of Thoracic Surgery | 2005 | 7 Pages |
Abstract
The 5-year survival rate in stage I, II, IIIA, and IV lung cancer with operable hematogenous brain metastases corresponds to that in the customary stage IIIA (23%). The disease-free interval exhibited no significant impact on the survival rate. The complaint-free status exhibits a significantly greater impact on the survival rate in hematogenic metastasis.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
József MD, PhD, Imre MD, Tamás MD, László MD, Attila MD, PhD, József MD, Egon MD, József PhD, László MD, PhD,